Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases

June 25, 2018, Society of Nuclear Medicine and Molecular Imaging
Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases
The chemical structures and brain PET images of the novel 18F-labeled SV2A PET tracers, 18F-SDM-7, 18F-SDM-8, and the lead tracer 11C-UCB-J in nonhuman primates. Credit: Z Cai and S Li et al., Yale University, New Haven, Conn.

New nuclear medicine tracers could help medical researchers find a cure for Alzheimer's and other neurodegenerative diseases. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

The development of therapies for has been hampered by the lack of a reliable and sensitive method to detect disease early and to effectively monitor the performance of experimental drugs. Synapse loss is one of the earliest and most robust biomarkers for Alzheimer's disease, and quantification of synaptic density in the central nervous system could be used to detect a variety of neurodegenerative diseases at their earliest stage, track progression and monitor the effect of therapy.

Positron emission tomography (PET) imaging can obtain crucial information about synaptic density that cannot be acquired through other approaches. Previous research identified a radiotracer (11C-UCB-J) for the synaptic vesicle protein 2 (SV2A) that was successfully used to image synaptic density in vivo; however, its characteristics were not conducive to clinical use.

"We set out to develop 18F-labeled SV2A tracers with imaging characteristics comparable to those of 11C-UCB-J," said Zhengxin Cai, Ph.D., of the Department of Radiology and Biomedical Imaging at Yale University. Cai, together with Songye Li, Ph.D., and colleagues from the Yale PET Center, were able to successfully synthesize and evaluate a number of novel SV2A tracers with attractive imaging properties: high brain uptake, fast tissue kinetics, and high specific binding signals in the brain. "With a longer half-life," Cai said, "our new tracers are suitable for multicenter clinical trials, routine clinical use and potential commercialization."

As new generations of drugs are undergoing clinical trials for neurodegenerative diseases, the new radiotracers will be able to facilitate the development of therapies, providing a novel tool for identifying which patients may benefit from a particular treatment and then for assessing its therapeutic effect.

"The successful development of our new SV2A PET tracers for synaptic density imaging and their use in the study of a variety of neurologic and psychiatric disorders will play a crucial role in CNS drug discovery and development," said Yiyun Henry Huang, professor of Radiology and Biomedical Imaging, Director of Chemistry at the Yale PET Center, and senior author of the research presented at the meeting.

Explore further: Scientists apply new imaging tool to common brain disorders

More information: Abstract 69: "In vivo imaging evaluation of a novel 18F-labeled SV2A PET tracer in nonhuman primates," Zhengxin Cai, Songye Li, Daniel Holden, Shu-fei Lin, Anupama Shirali, Paul Emery, Michael Kapinos, Jim Ropchan, Nabeel Nabulsi, Richard E. Carson and Yiyun Huang, Yale University, New Haven, CT; and Wenjie Zhang, West China Hospital, New Haven, CT. SNMMI 2018 Annual Meeting, June 23-26, 2018, Philadelphia. jnm.snmjournals.org/content/59 … 33-a2c3-ac4375122329

Related Stories

Scientists apply new imaging tool to common brain disorders

July 20, 2016
A Yale-led team of researchers developed a new approach to scanning the brain for changes in synapses that are associated with common brain disorders. The technique may provide insights into the diagnosis and treatment of ...

PET tracer gauges effectiveness of promising Alzheimer's treatment

December 6, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the first large-scale longitudinal imaging study to evaluate BACE1 inhibition with micro-PET in mouse models ...

Using tau imaging as diagnostic marker for Alzheimer disease

July 25, 2016
The accumulation of β-Amyloid (Αβ) and tau proteins in the brain is hallmark pathology for Alzheimer disease. Recently developed positron emission tomography (PET) tracers, including [18F]-AV-1451, bind to tau in neurofibrillary ...

Proteomics analyses could present new opportunities to diagnose and treat dementias

January 9, 2018
One of the most intriguing properties of the brain is its means to undergo synaptic plasticity which represents the basis for learning and memory, abilities that severely decline in the case of a dementia. New research, published ...

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

PET imaging with special tracer can detect and diagnose early Alzheimer's disease

May 24, 2016
The effort to find ways to detect and diagnose preclinical Alzheimer's disease (AD) has taken a big step forward with the use of positron emission tomography (PET), a "nuclear medicine" for imaging processes in the body, ...

Recommended for you

Practice imperfect—repeated cognitive testing can obscure early signs of dementia

July 12, 2018
Alzheimer's disease (AD) is a progressive, neurodegenerative condition that often begins with mild cognitive impairment or MCI, making early and repeated assessments of cognitive change crucial to diagnosis and treatment.

The 'Big Bang' of Alzheimer's: Scientists ID genesis of disease, focus efforts on shape-shifting tau

July 10, 2018
Scientists have discovered a "Big Bang" of Alzheimer's disease – the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.

'Skinny fat' in older adults may predict dementia, Alzheimer's risk

July 5, 2018
A new study has found that "skinny fat—the combination of low muscle mass and strength in the context of high fat mass—may be an important predictor of cognitive performance in older adults. While sarcopenia, the loss ...

Pathway of Alzheimer's degeneration discovered

July 5, 2018
Scientists at the Montreal Neurological Institute and Hospital (The Neuro) of McGill University have used a unique approach to track brain degeneration in Alzheimer's disease, uncovering a pathway through which degeneration ...

Brain study paves way for therapy for common cause of dementia

July 4, 2018
Scientists have uncovered a potential approach to treat one of the commonest causes of dementia and stroke in older people.

Sleep disorder linked with changes to brain structure typical of dementia

July 4, 2018
Obstructive sleep apnoea (OSA) is associated with changes to the structure of the brain that are also seen in the early stages of dementia, according to a study published in the European Respiratory Journal.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.